Installation of Elekta’s sixth high-field MR-adaptive linear accelerator initiated at The Christie

Research to focus on the use of MR-adapted radiotherapy in patients with lung
cancer
MANCHESTER, England, October 12, 2016 – Elekta (EKTA-B.ST), its MRI technology
partner Royal Philips (NYSE: PHG, AEX: PHIA) and The Christie NHS Foundation
Trust have initiated installation of an investigational high-field MR-adaptive
linear accelerator (MR-linac) system at The Christie.

Elekta’s MR-linac integrates an ultramodern radiotherapy system and a high-field
MRI scanner with sophisticated software. It will enable a physician to capture
high-quality images of tumors and surrounding tissues during radiation therapy
delivery. The MR-linac is designed to improve targeting of tumor tissue while
reducing exposure of healthy tissue to radiation. It could allow physicians to
precisely target a tumor, even when tumor tissue changes shape, location, size
or composition between treatment sessions.

The Christie is the sixth global site to install the MR-linac system, which is
already under functional evaluation at The Netherlands Cancer Institute;
University Medical Center Utrecht, the Netherlands; The University of Texas MD
Anderson Cancer Center, Houston Texas; and the Institute of Cancer Research,
working with its clinical partner The Royal Marsden NHS Foundation Trust in
London. Installation of an MR-linac system at the Froedtert & Medical College of
Wisconsin Clinical Cancer Center at Froedtert Hospital was initiated in
September 2016.

The Christie was an essential partner for Elekta in the development and use of
cone beam computed tomography (CBCT) image guidance at the time of treatment to
improve the delivery of radiotherapy, and has significant experience and
expertise that will help realize the potential of MR-linac and, in the future,
enable adaptive radiotherapy. It joined Elekta’s MR-linac research consortium in
2014. The consortium, a global collaboration of institutions focused on uniting
leaders in radiation oncology, MR imaging and physics, has a mission to
demonstrate that MR-linac technology can lead to improved patient outcomes for
existing radiation therapy indications and extend radiation therapy for
additional indications.

“The Christie has a history of innovation in the use of advanced imaging
technologies to improve the delivery of radiotherapy,” said Dr. Ananya
Choudhury, Consultant and Honorary Reader, Clinical Oncology at The Christie
“Our team has a number of visionary leaders in medical physics, MR imaging,
radiotherapy and clinical oncology. We are really excited to be part of this
global effort to bring the potential of MR-linac to The Christie and improve
outcomes for our patients.”

Professor Corinne Faivre-Finn, Honorary Consultant Clinical Oncologist and
Professor of Thoracic Radiation Oncology, is Tumor Site Group lead for lung
cancer in Elekta’s Global Research Consortium. She added: “The vision is that MR
-adapted radiotherapy will allow individualized and intensified treatment of
patients with lung cancer, leading to improved local control and survival with
no increase in toxicity. Currently, MR imaging is not used routinely for
radiotherapy planning in lung cancer. Therefore, ongoing research is focusing on
MR sequences that can be used for radiotherapy planning and the evaluation of
radiotherapy plans in the presence of a magnet. The group is developing clinical
studies in a number of patient groups who currently have a poor outcome after
radiotherapy treatment. Although The Christie will be leading on lung cancer
research within the Elekta consortium, we anticipate that MR-linac will be used
to treat patients with a wide range of cancers.”

Elekta and its global collaborators overcame significant engineering hurdles to
demonstrate the feasibility of the MR-linac technology. Previously, experts in
the field thought it nearly impossible to combine MRI and linear accelerator
devices because the powerful magnets used in MRI could interfere with radiation
beams.

“We are excited to initiate the installation of our sixth MR-linac system, and
are on track to complete installation at all seven consortium sites,” said Kevin
Brown, Elekta’s Global Vice President of Scientific Research. “Radiation therapy
is a critical component of lung cancer treatment, and we believe that MR-linac
will enable more effective delivery of radiation to lung tumors while sparing
healthy lung tissue and other nearby organs. Our global consortium is
exceptionally positioned to generate the data and protocols that will support
the use of MR-linac in lung cancer and other cancer indications.”

“As a leader in digital MRI technologies and image-guided therapy solutions, we
have been working hard with Elekta and consortium partners such as The Christie
to meet a set of ambitious milestones,” said Rob Cascella, CEO of the Diagnosis
and Treatment businesses at Royal Philips. “With excellent progress in the MR
-linac installations and validation of the technology, plus a global increase in
the use of MRI for radiotherapy planning, our journey to make a positive
difference in cancer care is gaining great momentum.”

Elekta’s MR-linac is a work in progress and not available for sale or
distribution.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

Steve Klink, Philips Group Communications
Tel: +31 610 888 824, e-mail: steve.klink@philips.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on October 12, 2016.

About Elekta
Elekta (NSE:EKTAb) is a human care company pioneering significant innovations
and clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning systems
for radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and resource
-efficient solutions that offer confidence to both health care providers and
patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people’s health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis, treatment and
home care. Philips leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. The company, headquartered in the
Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health and home care.
Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion
and employs approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at www.philips.com/newscenter.

About The Christie
The Christie opened in 1901 and is now one of Europe’s leading cancer centers
and the largest single-site centre in Europe. It has one of the largest
radiotherapy departments in the world as well as centers in Oldham and
Salford. It also houses the UK’s largest brachytherapy service. The Christie
delivers chemotherapy treatment through the largest chemotherapy unit in the UK,
as well as via 10 other sites, a mobile chemotherapy unit and in patients’
homes. We are ranked as the 9th most technologically advanced cancer center in
the world and the top center outside North America. The Christie’s NIHR Clinical
Research Facility is a large, high quality, dedicated clinical research
environment where our patients can participate in complex and early phase
clinical trials. Around 600 clinical trials may be taking place at any one time.
We are also one of seven partners in the Manchester Academic Health Science
Centre, one of only six health science centers in the country. New developments
include the UK’s first NHS high energy proton beam therapy service, due to start
treating patients in 2018.  The Christie was selected to deliver this specialist
treatment, along with University College London Hospitals NHS Foundation
Trust. Currently patients have to travel to America or Switzerland for this
treatment. The Christie’s School of Oncology provides undergraduate education,
clinical professional and medical education - the first of its kind in the UK.